CODEXIS INC

CDXSNASDAQ

🏆 #3884 by market capUS Equity

$1.36▼ $0.01 (−0.37%)

After hours · at close

🔔

Track CDXS

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 0.4%

7d▼ 3.2%

14d▼ 2.5%

30d▼ 14.8%

ytd▼ 16.6%

1y▼ 45.1%

🏦Market Cap

$146M

Small Cap

📈Revenue Growth (YoY)

+35.9%

High Growth

📊Gross Margin

87.0%

High

💵FCF Margin

25.2%

Strong

⚖️P/S Ratio

1.9x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $1.34 – $1.38
52-Week Range: $0.96 – $2.98
Volume: $4.48B
Avg Volume: $5.15B
Shares Outstanding: 107.6M
Next Earnings: Oct 17, 2026

Fundamentals Snapshot

Annual Revenue: $70M
Last Q Revenue: $15M
P/E Ratio: —
P/S Ratio: 1.9x
EPS (TTM): $-0.34
Dividend Yield: —
Dilution (1yr): +11.8%

Why Investors Own CDXS

✓High-growth profile — revenue up +51.7% YoY with expanding US Equity exposure.
✓Healthy economics — 68% gross margin and 12% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CODEXIS INC

CDXS

Financial Trends

Revenue

$70M▲ +18.6% YoY

Gross Margin

86.7%▲ +19.5% YoY

Operating Income

−$38M▼ −34.5% YoY

Free Cash Flow

−$24M▼ −55.6% YoY

Shares Outstanding

90.9M▲ +11.8% YoY

Net Cash

−$22M▲ +$18M YoY

StockOtter · stockotter.space

About CODEXIS INC

Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.

🦦